Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Wednesday 14 June 2017, 10:00 to 16:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present: 1. Chair Professor Andrew Stevens Present for all notes
2. Professor Kathryn Abel Present for all notes
3. Mr Kamal Balakrishnan Present for all notes
4. Mr Michael Chambers Present for all notes
5. Mr David Chandler Present for all notes
6. Mrs Gail Coster Present for all notes
7. Mr John P Hampson Present for all notes
8. Dr Nigel Langford Present for all notes
9. Dr Iain Miller Present for all notes
10. Professor Peter Selby Present for all notes
11. Professor Matt Stevenson Present for all notes
12. Dr Paul Tappenden Present for all notes
13. Mr Robert Walton Present for all notes
14. Dr Judith Wardle Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for all notes

Kate Moore Project Manager, National Institute for Health and Care Excellence Present for all notes

Alex Sexton Administrator, National Institute for Health and Care Excellence Present for all notes

Jessica Maloney Technical Analyst, Present for notes 5 to 15
1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy and venetoclax for treating chronic lymphocytic leukaemia.

2. The Chair informed the Committee of the non-public observers at this meeting: Christopher Eatough, Leslie Hayes, Michele Hilton Boon, Alice Murray and Lydia Shears.

3. Apologies were received from Dr Prithviraj Das, Professor Andrea Manca, Professor Stephen O’Brien and Professor Andrew Renehan.
Any other business

4. None

Appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID970]

Part 1 – Open session

5. The Chair welcomed the invited experts: Peter Clark, Sophie Beale, Jackie Fenemore, James Mahon, Sarah Nevitt and Yvonne Summers to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Roche to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Professor Andrew Stevens, Professor Kathryn Abel, Mr Kamal Balakrishnan, Mr David Chandler, Mrs Gail Coster, Mr John P Hampson, Dr Nigel Langford, Dr Iain Miller, Dr Peter Selby, Professor Matt Stevenson, Dr Paul Tappenden, Mr Robert Walton and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy

7.2. Mr Michael Chambers declared a personal non-specific financial interest as he has received payment from Roche Pharmaceuticals on topics unrelated to this appraisal topic.

7.2.1. It was agreed that this declaration would not prevent Mr Michael Chambers from participating in this section of the meeting.

7.3. The Chair asked all NICE Staff to declare any relevant interests.

7.4. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy.

8. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy.

9. The Chair introduced the lead team, Mrs Gail Coster, Dr Paul Tappenden and Dr Judith Wardle who gave presentations on the clinical effectiveness and cost
effectiveness of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy.

10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. Discussion on confidential information continued. This information was supplied by the company.

14. The Committee continued to discuss the clinical and cost effectiveness of atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy.

14.1. The committee decision was based on consensus.

15. The Committee instructed the technical team to prepare the Appraisal Consultation Document in line with their decisions.

Appraisal of venetoclax for treating chronic lymphocytic leukaemia [ID944]

Part 1 – Open session

16. The Chair welcomed the invited experts: Peter Clark, Dr Martin Connock, Professor James Mason and Professor Anna Schuh to the meeting and they introduced themselves to the Committee.

17. The Chair welcomed company representatives from AbbVie to the meeting.

18. The Chair asked all Committee members to declare any relevant interests

18.1. Professor Andrew Stevens, Professor Kathryn Abel, Mr Kamal Balakrishnan, Mr Michael Chambers, Mr David Chandler, Mrs Gail Coster, Mr John P Hampson, Dr Nigel Langford, Dr Iain Miller, Dr Peter Selby, Professor Matt Stevenson, Dr Paul Tappenden, Mr Robert Walton and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of venetoclax for treating chronic lymphocytic leukaemia.

19. The Chair asked all NICE Staff to declare any relevant interests.

19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or...
personal non-specific family interest for any of the technologies to be considered as part of the appraisal of venetoclax for treating chronic lymphocytic leukaemia.

20. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of venetoclax for treating chronic lymphocytic leukaemia.

21. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

22. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

23. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

24. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

25. Discussion on confidential information continued. This information was supplied by the company.

26. The Committee continued to discuss the clinical and cost effectiveness of venetoclax for treating chronic lymphocytic leukaemia.

26.1. The committee decision was based on consensus.

27. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

28. Wednesday 12 July 2017 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.